Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon Mobil ...
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.
Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...
Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...